Press Release

DIASORIN S.P.A. RECEIVES APPROVAL TO MARKET A NEW PRENATAL SCREENING PRODUCT LINE ON LIASON PLATFORM.

A broader CLIA menu to support recent geographic expansion decisions.

Saluggia, April 9, 2010. The SFDA (State Food and Drug Administration – China’s agency responsible for approving diagnostic products for marketing) approved DiaSorin’s application to market tests for Cytomegalovirus IgM, Rubella IgM and Herpes Simplex IgM. Thanks to these approvals, a total of 33 LIAISON tests are now available in China, where DiaSorin is currently the only supplier offering a complete prenatal screening panel (ToRCH IgM – Toxoplasmosis, Rubella, Cytomegalovirus, Herpes simplex virus) on fully automated CLIA technology.

The potential target market for these products in China is estimated at about $30 million. However, if demographic trends and recent statements by the local government about plans to provide basic health care coverage to 80% of the population are to be taken into account, estimates about market size may have to be revised substantially upward.

The completion of the prenatal screening panel, occurring concurrently with the conversion of the Chinese subsidiary from a non trading company into a commercial company that has been operating directly in the market since January of this year, represents another important step forward in the expansion strategy pursued by the Group, which views China as a key driver of its future growth.

Last year, the revenues generated in China by DiaSorin were already growing at a rate of 28.4% compared with 2008, as the installed base increased to 182 systems, 55 more than in 2008.

“The completion of the product line on the LIAISON platform offered in China, which now includes the prenatal screening tests,” said Carlo Rosa, Chief Executive Officer of DiaSorin S.p.A.,
“provides DiaSorin with an opportunity to strengthen its position in the Chinese market, which the Group has been cultivating for several years in light of its future growth potential. DiaSorin is already the European leader in the area of infectious diseases and intends to become the benchmark producer in this field also in China, where the government and the medical profession are viewing the use of these products with great interest.”

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 20 companies based in Europe, the United States, Central and South America and Asia. It has more than 1,100 employees, including about 110 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA) and Dublin (Ireland). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which it operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing. For additional information, please visit our website: www.DiaSorin.it

Contacts:

Investor Relations Officer
Laura Villa
DiaSorin S.p.A.
laura.villa@DiaSorin.it
+39 0161487532
+39 348 15 11 542

Ufficio Stampa
Carolina Mailander
c.mailander@mailander.it
+39 335 655 56 51
Bruno Caprioli
caprioli@mailander.it
+39 335 590 14 02